Hello all, I am hoping that some of you can interpret the...

Hello all,  I am hoping that some of you can interpret the results of this study, posted recently.

https://hal.inria.fr/hal-01237102/document

I am no expert, but my interpretation of the conclusion is as follows:
1) the study compares Y90 in conjunction with various other drugs including Gemcitabine, Oxaliplatin, paclitaxel and sorafenib.
2) The results presented here showed a strong synergistic effect between gemcitabine and 90Y .
3) While synergy between oxaliplatin and 90Y was shown in the cholangiocarcinoma cell lines, it was not the case in the HCC cell lines.
4) By contrast, paclitaxel and sorafenib showed antagonism with 90Y
5) this study supports the use of gemcitabine and oxaliplatin in combination with SIRT in HCC and ICC, but not the use of paclitaxel or sorafenib

I confess this is way outside my level of expertise.  Hopefully someone can put this into plain English with reference to SARAH, SIRveNIB and FOXFIRE trials underway.

Thanks!